Progerinin

Progerinin (SLC-D011) is an orally active progerin-lamin A binding inhibitor. Progerinin selectively binds to the C-terminal region of progerin, disrupting its interaction with lamin A and promoting progerin degradation while sparing wild-type lamin A, B, and C. Progerinin ameliorates nuclear deformation, increases H3K9me3 levels, and reduces progerin expression in HGPS patient-derived fibroblasts. Progerinin extends lifespan in LmnaG609G/G609G mice and LmnaG609G/+ mice, improves body weight, hair morphology, cardiac function, and histological phenotypes. Progerinin can be used for the study of Hutchinson-Gilford progeria syndrome (HGPS) [1].

Product Specifications

CAS Number

[2249696-72-6]

Product Name Alternative

SLC-D011

UNSPSC

12352005

Target

DNA/RNA Synthesis

Type

Reference compound

Related Pathways

Cell Cycle/DNA Damage

Applications

Cancer-programmed cell death

Field of Research

Others

Assay Protocol

https://www.medchemexpress.com/progerinin.html

Purity

99.74

Solubility

DMSO : 100 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

CC1(OC2=CC(OC(C=C3)=O)=C3C=C2C[C@@H]1OC/C=C/C4=CC=CC=C4)C

Molecular Formula

C23H22O4

Molecular Weight

362.42

References & Citations

[1]Kang SM, et al. Progerinin, an optimized progerin-lamin A binding inhibitor, ameliorates premature senescence phenotypes of Hutchinson-Gilford progeria syndrome. Commun Biol. 2021 Jan 4;4 (1) :5.